INBRX-106
Advanced Solid Tumors
Phase 1/2Active
Key Facts
About Inhibrx Biosciences
Inhibrx Biosciences is a public, clinical-stage biotech focused on developing differentiated biologics for high-need oncology indications. Its core innovation is a versatile single-domain antibody (sdAb) platform that enables the creation of multi-valent, conditionally active molecules with potential advantages over conventional antibodies. The company's strategy centers on advancing its two lead clinical assets, a tetravalent DR5 agonist for sarcoma and a hexavalent OX40 agonist for solid tumors, while leveraging its lean, protein-engineering expertise to create future pipeline candidates.
View full company profileTherapeutic Areas
Other Advanced Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| NT219 | Purple Biotech | Phase 1/2 |
| INDP-101 | Indaptus Therapeutics | Phase 1 |
| NST-101 (estimated) | Novastage Pharmaceuticals | Phase 1/2 |
| Meta10-TILs | Leman Biotech | Phase 1 |
| PM14 | PharmaMar | Phase 1/2 |
| Ecubectedin (PM54) | PharmaMar | Phase 1 |
| M8891 | Merck KGaA | Phase 1/2 |
| P-002 | Panacea Biotec | Phase 1/2 |
| Undisclosed kinase inhibitor | Tyligand Bioscience | Phase 1 |
| TYK-001 | TYK Medicines | Phase 1/2 |
| PT-112 | SciClone Pharmaceuticals | Phase 1 |
| AP-202 | Advance Pharmaceutical | Phase 1/2 |